Psychedelic Drug Stocks Index Up Slightly This Week

psychedelic stocks

There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and here is how its constituents performed this week, in descending order, since the end of August (i.e. 5 weeks) and YTD:

  1. Allied Corp. (ALID): UP 31.1% this week; UP 37.2% in last 5 weeks; DOWN 66.7%YTD
    • Has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder.
  2. Cybin (CYBN): UP 25.0% this week; DOWN 43.4% in last 5 weeks; DOWN 50.0% YTD
    • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
  3. Compass Pathways (CMPS): UP 8.8% this week; DOWN 30.4% in last 5 weeks; DOWN 47.2% YTD
    • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
  4. GH Research (GHRS): UP 3.8% this week; DOWN 24.1% in last 5 weeks; DOWN 48.3% YTD
    • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
  5. Seelos (SEEL): UP 1.9% this week; UP 25.0 % in last 5 weeks; DOWN 35.6% YTD
    • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.
  6. Atai (ATAI): UP 1.8% this week; DOWN 22.7% in last 5 weeks; DOWN 55.8% YTD
    • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
  7. Zynerba (ZYNE): UP 1.4% this week; DOWN 33.9% in last 5 weeks; DOWN 74.3% YTD
    • Is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery.
  8. Mind Medicine (MNMD): DOWN 12.0% this week; DOWN 73.2% in last 5 weeks; DOWN 85.1% YTD
    • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
    • Underwent a 1-for-15 reverse stock exchange on August 29th.

In total, the munKNEE Psychedelic Drug Stock Index went UP 4.1% this week (DOWN 8.9% the previous week), has gone DOWN 35.6% in the last 5 weeks and is now DOWN 59.2% YTD.

Six other psychedelic companies are primarily focused on the development, expansion and operation of ketamine-assisted therapy (KAT) clinics to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction and substance abuse withdrawal, and depression. They are identified below with a description of each of their commercialization developments:

  1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF)
    • Is concentrating on the treatment of Alcohol Use Disorder (AUM)
      • has 3 KAT clinics, 2 in the U.K. and 1 in Norway and
      • is developing MDMA-assisted therapy for AUM
    •  Is also in the process of developing KAT for Gambling Disorder
    • Go here for the company's latest quarterly (Q2) financial results.
  2. Delic Corp. (CSE: DELC|OTCQB: DELCF)
    • Has 13 ketamine-assisted therapy (KAT) clinics in the U.S.
  3. Field Trip Health and Wellness Ltd. (TSXV:FTHW|OTCQB:   FTHWF)
    • Is concentrating on therapies for the treatment of resistant depression, post-traumatic stress disorder and disorders affecting the central nervous systems;
    • Operates KAT clinics in Canada (3), the U.S. (8) and Europe (1)
  4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF)
    • has 3 KAT clinics in Canada;
    • has the ability to undertake treatments using psilocybin and MDMA in Canada as authorized by Health Canada's Special Access Program;
    • Has 6 KAT clinics in Utah and 2 in Arizona
  5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB:   RVLWF)
    • Has 10 KAT clinics in 6 states and 9 options on other clinics
  6. Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)
    • Is concentrating on the treatment of Opioid Use Disorder using ibogaine which has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the US) facilitating research and development toward medicalization

The  above psychedelic-assisted therapy clinic stocks went DOWN 6.1%, on average, this week and are now DOWN 25.2% in the last 5 weeks.

More By This Author:

Decline In Plant-Based Food Stocks Index Slowed This Week
September Cannabis Category Performances Ranged From -6.3% To -39.0%
Major Plant-Based Food Stocks Continued To Decline In September

Visit and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.